Raising awareness of a silent crisis
Non-alcoholic fatty liver disease is increasingly common, but reversible.
Like many patients, Tony Villiotti had never heard of non-alcoholic fatty liver disease (NAFLD) when his doctor first told him about this increasingly common condition. But after his condition slowly and silently worsened, resulting in liver cancer and finally a liver transplant, he founded a non-profit organization to raise awareness of how early diagnosis and intervention can prevent devastating consequences.
A growing threat
Progression and complications
Non-alcoholic fatty liver disease progression and regression
Healthy liver
Saving lives through awareness
More information on liver health
[1] Younossi et al., Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431.
[2] Estes et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018 Jan;67(1):123-133. doi: 10.1002/hep.29466.
[3] Hamaguchi et al., The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005 Nov 15;143(10):722-8. doi:10.7326/0003-4819-143-10-200511150-00009
[4] Arshad et. al., Nonalcoholic Fatty Liver Disease Prevalence Trends Among Adolescents and Young Adults in the United States, 2007-2016. Hepatol Commun, 5: 1676-1688. doi: 10.1002/hep4.1760
[5] Shi et al, The Prevalence of Lean/Nonobese Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2020 Apr;54(4):378-387. doi: 10.1097/MCG.0000000000001270
[6] Heimbach et al., A bridge too far--liver transplantation for nonalcoholic steatohepatitis will overwhelm the organ supply. Liver Transpl. 2014 Nov;20 Suppl 2:S32-7. doi:10.1002/lt.23980.
[7] Fernando et. al., Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products. Int J Mol Sci, 2019;20(20):5037. doi:10.3390/ijms20205037
[8] Younossi et al., The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016 Nov;64(5):1577-1586. doi: 10.1002/hep.28785
[9] Estes et al., Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology, 67: 123-133. doi: 10.1002/hep.29466The statements by Siemens Healthineers customers described herein are based on results that were achieved in the customer’s unique setting. Since there is no “typical” hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results.